Contrarian Corpus
activist conference presentation initial thesis
2024-04-03 · 47 pages

Solvay SA SOLB BB

Post-spin Solvay — a #1 essential-chemicals business — trades at ~7x trough 2024 EPS with ~10% dividend yield; normalized 2028 earnings support roughly doubling the stock.

N 4 Narrative
V 3 Visual
C 2 Craft
Original source ↗

Thesis

Greenlight's April 2024 Sohn pitch is the post-spinoff 'new Solvay' (SOLB BB), a 160-year-old Belgian essential-chemicals business that shed its specialty arm as Syensqo in December 2023. Solvay holds #1 global positions in soda ash, peroxides, silica, special chem and Coatis — boring but high-margin commodity lines delivering 25.5% EBITDA margins, 20.4% ROCE and modest 1.2x leverage. 2024 is a trough year: European destocking, a soda-ash price reset and energy-cost normalization drive EPS from €5.40 in 2023 to ~€3.62-€4. The sell-side has capitulated to underweight with €21.50 price targets, yet at €25.30 the stock trades at ~7x depressed earnings with a ~10% dividend yield. Management's 2028 targets imply ~€6.79 EPS. At twice the price, Einhorn argues, it still wouldn't look expensive.

SCQA

Situation

Solvay is a 160-year-old Belgian essential-chemicals business that, post-December 2023 spinoff of Syensqo, holds #1 global positions across soda ash, peroxides, silica, special chem and Coatis with 25.5% EBITDA margins.

Complication

2024 is a cyclical trough — European destocking, a soda-ash pricing reset and energy normalization cut EPS from €5.40 to ~€3.62, driving sell-side underweights and a 7x multiple despite the decline being transient, not structural.

Resolution

Buy the stock at €25.30 and collect the near-10% dividend while management executes its 2028 plan: mid-single-digit EBITDA growth, mid-to-high-20s margins, €300mn run-rate gross savings, investment-grade balance sheet.

Reward

Normalized 2028 EPS of ~€6.79 at a still-cheap multiple supports roughly doubling the stock — 'at twice the price, it wouldn't seem expensive' — plus ~10% annual dividend yield en route.

The three reasons

  1. 1

    Post-spin 'new Solvay' is a #1-position essential chemicals business at 7x trough 2024 EPS

  2. 2

    2024 is cyclical trough; 2028 targets imply ~€6.79 EPS near prior peak

  3. 3

    Near-10% dividend yield returns half the market cap over five years

Primary demands

  • Buy the post-spinoff 'new Solvay' as a value long at ~7x trough 2024 earnings
  • Collect the near-10% dividend while management executes its 2028 plan
  • Own it into a normalization of European chemicals earnings toward the 2028 targets

KPIs cited

EBITDA margin
25.5% in 2023 (record); mid-to-high-20s 2028 target
ROCE
20.4% from continuing operations; low-20s by 2028
Net leverage
1.2x underlying net debt / EBITDA
P/E multiple
~7x on 2024E EPS of €3.62 consensus (Greenlight sees ~€4)
Dividend yield
€2.43 2023 dividend on €25.30 share price ≈ 9.6%
2028 EPS
~€6.79 at midpoint of management's 2028 targets, near prior €6.01 peak
Five-year FCF
~€4bn pre-CAPEX 2024-28, roughly equal to €2.7bn market cap
Segment mix
Soda Ash 43%, Special Chem 19%, Peroxides 13%, Coatis 13%, Silica 12% of sales

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • Warren Buffett in the 1950s — a 'great time to be a value investor' analogue for today's thinned-out active management

Notable slides (6)

Notes

Sohn Investment Conference 2024 pitch by David Einhorn. 'Solve-AI' is deliberate wordplay — Einhorn pitches boring Belgian chemicals into the AI-mania zeitgeist. This is a long value idea, not an activist campaign: no demands on management, no board agitation, tone is collegial (slide 42 quotes Solvay favorably). Greenlight genre rather than typical activist deck — classic Einhorn Sohn style with chemistry jokes and CartoonStock cartoons as connective tissue. Stake size not disclosed in deck. Document type = conference_presentation given the explicit Sohn framing on the cover. Campaign_phase = initial_thesis (first public pitch of this idea).